Androgen deprivation therapy (ADT) is the most common non-surgical initial treatment for recurrent and treatment-naïve metastatic prostate cancer due to the universal and pivotal roles of androgens and androgen receptor (AR) in prostate growth and development and early stage prostate cancers (Shafi et al., 2013). This evidence concerns the gene AR and prostate carcinoma.